Table 2.
Details of patients affected by breast cancer under bone modifying agents for CTIBL
| N. 15 BC patients with CTIBL (%) | |
|---|---|
| Median age | 68 |
| Mean age ± SD | 67.5 ± 11 |
| Comorbidities | Yes 8 (53.3) |
| No 7 (46.7) | |
| Diabetes | 2 (13.3) |
| Hypertension | 7 (46.7) |
| HCV-related hepatopathy | 0 |
| Arthrosis | 1 (6.7) |
| Cardiovascular diseases | 0 |
| Corticosteroid therapy | 5(33.3) |
| Site of MRONJ | |
| Mandible | 11 (73.3) |
| Maxilla | 4 (26.7) |
| Mandible and Maxilla | 0 |
| Oral trigger for MRONJ | Yes 10 (66.7) |
| No 5 (33.3) | |
| Tooth extraction | 6 (40) |
| Periodontal disease | 3 (20) |
| Peri-implantitis | 1 (6.66) |
| Prosthetic trauma | 0 |
| MRONJ stage according to AAOMS | |
| 1 | 5 (33.3) |
| 2 | 6 (40) |
| 3 | 4 (26.7) |
| MRONJ stage according to SICMF–SIPMO | |
| 1 | 5 (33.3) |
| 2 | 6 (40) |
| 3 | 4 (26.7) |